Cancer is the leading cause of disease and death in the world, but a clinically proven circulating biomarker that can be used to help guide patient management will be available for only a minority of cancer patients. A new generation of biomarkers has become available with the discovery of the genetic alterations that are responsible for the initiation and progression of human cancers.
Zinexts will focus on a non-invasive approach that enables disease screening and diagnosis based on blood or urine samples. Evaluation of circulating-free DNA (cfDNA) or circulating tumor cells (CTCs) with biomarkers in liquid biopsy would be typical tools to screen, diagnose, and monitor cancer in the future. Otherwise, the epigenetic test (i.e., DNA methylation) is currently a new area of cancer biomarkers that are implemented into clinical practice. Our aim is to provide molecular diagnostic solutions for cancer screening, especially focusing on the fields of CTCs, cfDNA, and DNA methylation biomarkers.
Zinexts will focus on a non-invasive approach that enables disease screening and diagnosis based on blood or urine samples. Evaluation of circulating-free DNA (cfDNA) or circulating tumor cells (CTCs) with biomarkers in liquid biopsy would be typical tools to screen, diagnose, and monitor cancer in the future. Otherwise, the epigenetic test (i.e., DNA methylation) is currently a new area of cancer biomarkers that are implemented into clinical practice. Our aim is to provide molecular diagnostic solutions for cancer screening, especially focusing on the fields of CTCs, cfDNA, and DNA methylation biomarkers.
